In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

(2020) Richard G Wunderink et al.   LANCET INFECTIOUS DISEASES

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

(2020) Naoki Kohira et al.   Journal of Global Antimicrobial Resistance

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection

(2020) Nao Kawaguchi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options

(2019) Chau-Chyun Sheu et al.   Frontiers in Microbiology

Resistance mechanisms and population structure of highly drug resistant Klebsiella in Pakistan during the introduction of the carbapenemase NDM-1

(2019) Eva Heinz et al.   Scientific Reports

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

(2019) Takafumi Sato et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria

(2019) Patrice Nordmann et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin

(2019) Takayuki Katsube et al.   CLINICAL INFECTIOUS DISEASES

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections

(2019) Yohei Doi   CLINICAL INFECTIOUS DISEASES

Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis

(2018) Nao Kawaguchi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region

(2018) Carlos Andrés Vargas-Alzate et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Relationship Between Biofilm Formation and Antimicrobial Resistance in Gram-Negative Bacteria

(2018) Virginio Cepas et al.   Microbial Drug Resistance

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

(2018) James A. Karlowsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

(2018) Krystyna M. Kazmierczak et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing

(2018) Sònia Martínez-Servat et al.   Frontiers in Microbiology

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

(2016) David van Duin et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014

(2016) Lindsey M. Weiner et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options

(2015) Ya-Ting Chang et al.   Frontiers in Microbiology